Part-Time
Posted on 5/9/2026
Early-stage life science venture investor
$71k - $101.2k/yr
Falmouth, MA, USA
In Person
Onsite role; primary Mashpee and Harwich, MA with exposure to other sites.
Mass General Brigham Ventures funds early-stage life science ideas arising from Mass General Brigham’s research network. It provides first access to deal flow and proprietary rights, backing the formation and growth of new companies and technologies. It uses capital and support to help translate bold innovations into drugs and medical technologies that improve patient outcomes worldwide.
Company Size
1-10
Company Stage
N/A
Total Funding
$1.7B
Headquarters
Cambridge, Massachusetts
Founded
2008
Help us improve and share your feedback! Did you find this helpful?
People at Mass General Brigham who can refer or advise you
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
Flexible Work Hours
Remote Work Options
Hybrid Work Options
Paid Vacation
Paid Sick Leave
Paid Holidays
Family Planning Benefits
Fertility Treatment Support
Professional Development Budget
Conference Attendance Budget
Wellness Program
Mental Health Support
Gym Membership
Phone/Internet Stipend
Home Office Stipend
Stock Options
Company Equity
401(k) Company Match
Parental Leave
Adoption Assistance
Childcare Support
Relocation Assistance
Employee Referral Bonus
Tuition Reimbursement
Professional Certification Support
Mentorship Program
Meal Benefits
Commuter Benefits
Legal Services
Employee Discounts
Company Social Events
Approximately 450 clinicians at Mass General Brigham Home Care, represented by the Massachusetts Nurses Association, will hold an informational picket on 24 March outside Massachusetts General Hospital. The clinicians are seeking their first union contract after more than 20 bargaining sessions since March 2025. The bargaining unit includes registered nurses, occupational therapists, physical therapists, speech language pathologists, social workers and dieticians who voted to join the MNA in June 2024. They are demanding reasonable caseload limits, clear productivity standards, competitive wages and recruitment protections. MGB reported a $59.2 million operating gain in the year ending September 2025, with CEO Dr Anne Klibanski's compensation rising 40% to $8.4 million in 2024. The picket is scheduled for 15:30 to 17:00 and is not a strike.
Avidity Partners has participated in a $40 million Series C funding round for Affinia Therapeutics, a company specializing in adeno-associated virus (AAV) gene therapies.
Predicta Biosciences, a precision oncology company developing novel diagnostic and therapeutic discovery solutions, today announced it has raised an oversubs...
Carta Healthcare has secured $18 million in Series B1 funding to enhance its AI-powered clinical data abstraction and analytics. The investment, led by UPMC Enterprises with participation from several health ventures, will support Carta's growth in the life sciences market. The funding follows Carta's acquisition of Realyze Intelligence and aims to expand its customer base and improve healthcare data management. CEO Brent Dover highlighted the investment's role in scaling operations and product deployment.
Sanofi-backed Abcuro has secured